Dry eye payday

With positive Phase III results for dry eye, SARcode Bioscience Inc. was thinking through the NDA process as well as the commercial launch of its lifitegrast. But a competitive bidding process that led to last week's acquisition by Shire plc (LSE:SHP; NASDAQ:SHPG) led the biotech and its investors to take the bird in hand.